Clinical Trial Update: Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating preoperative digoxin immune Fab (Digifab) in patients undergoing coronary artery bypass grafting to reduce ouabain levels and prevent a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Digifab (digoxin immune Fab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Acute Kidney Injury | Phase 4 | Status: COMPLETED | Results posted: 2025-07-02